AVNS
Avanos Medical, Inc. · Healthcare · Medical Devices
Last
$14.09
−$0.40 (−2.76%) 4:00 PM ET
After hours $14.10 +$0.01 (+0.07%) 8:42 PM ET
Prev close $14.49
Open $14.28
Day high $14.45
Day low $13.77
Volume 957,713
Avg vol 615,968
Mkt cap
$654.51M
P/E ratio
-8.97
FY Revenue
$701.20M
EPS
-1.57
Gross Margin
50.47%
Sector
Healthcare
AI report sections
AVNS
Avanos Medical, Inc.
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
+61% (Above avg)
Vol/Avg: 1.61×
RSI
55.28 (Neutral)
Neutral (40–60)
MACD momentum
Intraday
-0.01 (Weak)
MACD: 0.01 Signal: 0.02
Short-Term
-0.13 (Weak)
MACD: 0.50 Signal: 0.63
Long-Term
-0.03 (Weak)
MACD: 0.93 Signal: 0.96
Intraday trend score 63.00

Latest news

AVNS 12 articles Positive: 3 Neutral: 2 Negative: 0
Neutral The Motley Fool • The Motley Fool
Avanos (AVNS) Q2 2025 Earnings Call Transcript

Avanos Medical reported Q2 2025 financial results, highlighting strong performance in Specialty Nutrition Systems and Pain Management segments, while divesting its hyaluronic acid product line. The company maintained full-year revenue and earnings guidance despite tariff challenges and leadership changes.

AVNS earnings medical devices nutrition systems pain management tariffs divestiture
Sentiment note

Mixed financial performance with 2% organic sales growth, maintained guidance, strategic divestiture, but facing tariff challenges and recording a $77 million goodwill impairment charge

Positive GlobeNewswire Inc. • Researchandmarkets.Com
United States Syringes, Needles and Urinary Catheters Market Outlook to 2033: A Comprehensive Analysis of Current Trends and Future Projections

The report provides a comprehensive analysis of the United States market for syringes, needles, and urinary catheters, including market data, company profiles, and industry trends from 2018 to 2033.

BDX CAH SYK AVNS syringes needles urinary catheters United States
Sentiment note

The company is a major player in the United States syringes, needles, and urinary catheters market, and the report provides an overview of its operations and financial performance.

Neutral GlobeNewswire Inc. • Allied Market Research
Bio Pharma Buffer Market to Reach $2.4 Billion, Globally, by 2033 at 7.8% CAGR: Allied Market Research

The global bio pharma buffer market is expected to grow from $1.1 billion in 2023 to $2.4 billion by 2033, driven by the rising demand for biopharmaceuticals and the need for high-quality buffers in drug development and manufacturing.

BDX CAH CRL AVNS bio pharma buffer biopharmaceuticals drug development manufacturing
Sentiment note

The article mentions Avanos Medical as one of the key players in the bio pharma buffer market, but does not provide any specific information about the company's performance or outlook.

Positive Benzinga • Globe Newswire
Pain Management Devices Market to Witness 21.5 % CAGR by 2031 | SkyQuest Technology

The global pain management devices market is projected to grow at a CAGR of 21.5% from 2024 to 2031, driven by the increasing prevalence of chronic diseases and the rising demand for non-invasive pain management solutions.

BAX AVNS pain management devices chronic diseases non-invasive pain management
Sentiment note

The article includes Avanos Medical as one of the leading companies in the pain management devices market, implying its strong presence and market share.

Positive Zacks Investment Research • N/A
Is Phibro (PAHC) Stock Worth Retaining in Your Portfolio Now?

Phibro Animal Health Corporation's robust sales of vaccines and medicated feed additives (MFAs) are driving growth in its Animal Health business. The company's focus on advancing nutritional specialties and vaccine technologies, along with a new vaccine production unit, instills optimism. However, adverse macroeconomic impacts and growing competition from generic alternatives are concerns.

PAHC HAE AVNS TFX Phibro Animal Health Corporation vaccines medicated feed additives Animal Health business
Sentiment note

The article highlights Avanos Medical as a top-ranked stock with an estimated 34.9% earnings growth rate for 2024 and a history of earnings surprises.

Unknown Zacks Investment Research • Zacks Equity Research
Globus Medical (GMED) Up 7.4% Since Last Earnings Report: Can It Continue?

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

GMED AVNS
Unknown Zacks Investment Research • Zacks Equity Research
Why Is Integra (IART) Up 26% Since Last Earnings Report?

Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IART AVNS
Unknown Zacks Investment Research • Zacks Equity Research
Avanos (AVNS) Q1 Earnings & Revenues Surpass Estimates

Avanos' (AVNS) first-quarter results show strong bottom-line improvement along with decent growth in segmental revenues.

BSX ECL ALGN AVNS
Unknown Zacks Investment Research • Zacks Equity Research
Avanos Medical (AVNS) Q1 Earnings Beat Estimates (Revised)

Avanos Medical (AVNS) delivered earnings and revenue surprises of +4.76% and 1.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

AVNS OFIX
Unknown Zacks Investment Research • Zacks Equity Research
Avanos Medical (AVNS) Q1 Earnings Lag Estimates

Avanos Medical (AVNS) delivered earnings and revenue surprises of -9.52% and 1.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

AVNS OFIX
Unknown Zacks Investment Research • Zacks Equity Research
Three Reasons to Retain Avanos (AVNS) Stock in Your Portfolio

Avanos' (AVNS) strong product line and focus on R&D raise optimism about the stock.

DVA CAH COR AVNS
Unknown Zacks Investment Research • Zacks Equity Research
Why Is Integra (IART) Down 4% Since Last Earnings Report?

Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IART AVNS
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal